An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation



Status:Recruiting
Conditions:Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:60 - Any
Updated:4/6/2019
Start Date:December 30, 2015
End Date:July 28, 2022
Contact:Associate Director Clinical Trial Disclosure
Email:clinicaltrialdisclosure@celgene.com
Phone:1-888-260-1599

Use our guide to learn which trials are right for you!

A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

This is an international, multicenter, open-label, randomized, Phase 3 study comparing the
efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years
or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or
third-line AML therapy and positive for an isocitrate dehydrogenase (IDH2) mutation.

Acute myeloid leukaemia (AML) is a form of cancer that is common in older patients. Mutations
in the isocitrate dehydrogenase enzyme 2 (IDH2) have been found in approximately 15% of
patients with AML.

The outcome of first line chemotherapy treatment is poor and many patients fail to attain
complete remission (CR, ie refractory) or will eventually relapse. There is no single
standard of care for relapsed or refractory AML. Since the prognosis is very poor there is a
great need for new therapies.

Inhibition of the mutant IDH2 enzyme may represent a promising targeted therapy for AML.
AG-221 is a small molecule inhibitor of the IDH2 enzyme, designed to preferentially target
the mutant IDH2 variants. Data from the ongoing first-in-human study has shown AG-221 to be
generally well tolerated and demonstrated CR in patients with IDH2 mutation positive relapsed
or refractory AML.

The study purpose is to test the safety and efficacy of AG-221 compared with conventional
care regimens (CCR), which include best supportive care (BSC) only, azacitidine plus BSC,
low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, in patients with late
stage AML refractory to or relapsed after second or third line therapy and positive for the
IDH2 mutation. Patients will be randomly assigned to receive open-label tablets of AG-221 or
one of the CCR on continuous 28-day treatment cycles. The trial duration is expected to be 78
months which includes 42 months enrollment, approximately 7 months treatment and a follow-up
period.

Study procedures include: vital signs, physical exams, ECGs, ECHO, urine/blood samples, bone
marrow aspirates and/or biopsies and peripheral blood to test for IDH2 and assess treatment
response. Bone marrow, blood, cheek swab samples will be used for genetic tests.

This study is being sponsored by Celgene Corporation. Approximately 316 participants will
take part in the study.

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

1. Subject is ≥ 60 years of age at the time of signing the ICF

2. Subject has primary (ie, de novo) or secondary (progression of MDS or
myeloproliferative neoplasms ([MPN], or therapy-related) AML according to WHO
classification (Appendix B)

3. Subject has received second- or third-line of AML therapy (see Appendix G for the
definition of prior AML line; note that, for subjects having AML secondary to prior
higher risk [Intermediate-2 or High risk according to the International Prognostic
Scoring System] MDS treated with a hypomethylating agent [eg, azacitidine or
decitabine], the hypomethylating therapy can be counted as a line if there is disease
progression to AML during or shortly [eg, within 60 days] after the hypomethylating
therapy.)

4. Subject has the following disease status:

1. Refractory to or relapsed after second- or third-line of intensive therapy for
AML (eg, the "7 + 3" regimen):

at least 5% leukemic blasts in bone marrow (the minimum number of treatment
cycles of the intensive therapy is per the investigator's discretion); or

2. Refractory to or relapsed after second- or third-line low-intensity AML therapy
(eg, LDAC, azacitidine or decitabine):

at least 5% leukemic blasts in bone marrow after at least 2 treatment cycles

5. Subject is eligible for and willing to receive the pre-selected CCR treatment option,
according to the investigator's assessment (Note: Subjects with degenerative and toxic
encephalopathies, especially after the use of methotrexate or treatment with ionizing
radiation, should not receive cytarabine.)

6. Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
(Appendix D)

7. Subject has IDH2 gene mutations tested centrally (using the "investigational use
only"PCR assay, Abbott RealTime IDH2) in samples of bone marrow aspirate and
peripheral blood, and confirmed positive in bone marrow aspirate and/or peripheral
blood. (Note: in the event that the central laboratory result is delayed and precludes
acute clinical management of a subject who has confirmed IDH2 gene mutation by local
evaluation, the subject may be eligible for randomization with approval by the Medical
Monitor.)

8. Subject has adequate organ function defined as:

- Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT)
and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ≤ 3
x upper limit of normal (ULN), unless considered due to leukemic organ
involvement, following review by the Medical Monitor; and

- Serum total bilirubin ≤ 1.5 x ULN, unless considered due to Gilbert's syndrome
(eg, a gene mutation in UGT1A1) or leukemic organ involvement, following review
by the Medical Monitor; and

- Creatinine clearance > 30 mL/min based on the Modification of Diet in Renal
Disease (MDRD) glomerular filtration rate (GFR):

GFR (mL/min/1.73 m2) = 175 × (serum creatinine)-1.154 × (Age)-0.203 × (0.742 if
female) × (1.212 if African American)

9. Females of childbearing potential (FCBP)* may participate, providing they meet the
following conditions:

- Agree to practice true abstinence from sexual intercourse or to use highly
effective contraceptive methods (eg, combined [containing estrogen and
progestogen] or progestogen-only associated with inhibition of ovulation, oral,
injectable, intravaginal, patch, or implantable hormonal contraceptive; bilateral
tubal occlusion; intra-uterine device; intrauterine hormone-releasing system; or
male partner sterilization [note that vasectomized partner is a highly effective
birth control method provided that partner is the sole sexual partner of the FCBP
trial participant and that the vasectomized partner has received medical
assessment of the surgical success]) at screening and throughout the study, and
for 4 months following the last study treatment (6 months following the last dose
of cytarabine); and

- Have a negative serum β-subunit of human chorionic gonadotropin (β-hCG) pregnancy
test (sensitivity of at least 25 mIU/mL) at screening; and

- Have a negative serum or urine (investigator's discretion under local
regulations) β-hCG pregnancy test (sensitivity of at least 25 mIU/mL) within 72
hours prior to the start of study treatment in the Treatment Phase (note that the
screening serum pregnancy test can be used as the test prior to the start of
study treatment in the Treatment Phase if it is performed within the 72-hour
timeframe).

10. Male subjects must agree to practice true abstinence from sexual intercourse or to the
use of highly effective contraceptive methods (as described above) with non-pregnant
female partners of childbearing potential at screening and throughout the course of
the study, and should avoid conception with their partners during the course of the
study and for 4 months following the last study treatment (6 months following the last
dose of cytarabine; 6 months following the last dose of azacitidine in Canada)

11. Subject must understand and voluntarily sign an ICF prior to any study-related
assessments/procedures being conducted

12. Subject is willing and able to adhere to the study visit schedule and other protocol
requirements

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Subject is suspected or proven to have acute promyelocytic leukemia based on
morphology, immunophenotype, molecular assay, or karyotype

2. Subject has AML secondary to chronic myelogenous leukemia

3. Subject has received a targeted agent against an IDH2 mutation

4. Subject has received systemic anticancer therapy or radiotherapy < 14 days prior to
the start of study treatment. Note that hydroxyurea is allowed prior to the start of
study treatment for the control of leukocytosis (however, hydroxyurea should not be
given within 72 hours prior to and after administration of azacitidine).

5. Subject has received non-cytotoxic or investigational agents < 14 days or 5
half-lives, whichever is longer, prior to the start of study treatment

6. Subject has undergone HSCT within 60 days prior to the start of study treatment, or on
immunosuppressive therapy post HSCT at the time of screening, or with clinically
significant graft-versus-host disease (GVHD). The use of a stable dose of oral steroid
post-HSCT and/or topical steroids for ongoing skin GVHD is permitted.

7. Subject has persistent, clinically significant non-hematologic toxicities from prior
therapies

8. Subject has or is suspected of having central nervous system (CNS) leukemia.
Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is
suspected during screening.

9. Subject has active uncontrolled systemic fungal, bacterial, or viral infection
(defined as ongoing signs/symptoms related to the infection without improvement
despite appropriate antibiotics, antiviral therapy, and/or other treatment)

10. Subject has immediately life-threatening, severe complications of leukemia such as
uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated
intravascular coagulation

11. Subject has significant active cardiac disease within 6 months prior to the start of
study treatment, including New York Heart Association (NYHA) class III or IV
congestive heart failure (Appendix E); acute coronary syndrome (ACS); and/or stroke;
or left ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or
multi-gated acquisition (MUGA) scan obtained within 28 days prior to the start of
study treatment

12. Subject has prior history of malignancy, other than MDS, MPN or AML, unless the
subject has been free of the disease for ≥ 1 year prior to the start of study
treatment.

However, subjects with the following history/concurrent conditions are allowed:

- Basal or squamous cell carcinoma of the skin

- Carcinoma in situ of the cervix

- Carcinoma in situ of the breast

- Incidental histologic finding of prostate cancer (T1a or T1b using the tumor,
node, metastasis clinical staging system)

13. Subject is known seropositive or active infection with human immunodeficiency virus
(HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)

14. Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other
conditions that limit the ingestion or gastrointestinal absorption of drugs
administered orally

15. Subjects has uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or
diastolic BP > 100 mmHg)

16. Subject is a pregnant or lactating female

17. Subject has known or suspected to have hypersensitivity to any of the components of
study treatment

18. Subject is taking those medications (listed in Section 8.2) that are known to prolong
QT interval unless the subject can be transferred to other medications at least 5
half-lives prior to the start of study treatment

19. Subject has QTc interval (ie, Fridericia's correction [QTcF]) ≥ 450 ms or other
factors that increase the risk of QT prolongation or arrhythmic events (eg, heart
failure, hypokalemia, family history of long QT interval syndrome) at screening

20. Subject is taking the following sensitive CYP substrate medications that have a narrow
therapeutic range are excluded from the study unless the subject can be transferred to
other medications at least 5 half-lives prior to the start of study treatment:
paclitaxel and docetaxel (CYP2C8), phenytoin (CYP2C9), S-mephenytoin (CYP2C19),
thioridazine (CYP2D6), theophylline, and tizanidine (CYP1A2)

21. Subject is taking the breast cancer resistance protein (BCRP) transporter-sensitive
substrate rosuvastatin should be excluded from the study unless the subject can be
transferred to other medications at least 5 half-lives prior to the start of study
treatment

22. Subject has any significant medical condition, laboratory abnormality, or psychiatric
illness that would prevent the subject from participating in the study

23. Subject has any condition including the presence of laboratory abnormalities, which
places the subject at unacceptable risk if he/she were to participate in the study

24. Subject has any condition that confounds the ability to interpret data from the study
We found this trial at
27
sites
?
mi
from
Houston, TX
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
(773) 702-1000
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Concord, New South Wales
?
mi
from
Concord,
Click here to add this to my saved trials
Dallas, Texas 75246
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Evanston, IL
Click here to add this to my saved trials
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Greenville, South Carolina 29605
?
mi
from
Greenville, SC
Click here to add this to my saved trials
92 2nd St
Hackensack, New Jersey 07601
(201) 996-5900
John Theurer Cancer Center at the Hackensack University Medical Center The mission of the John...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
Morgantown, West Virginia 25606
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Nashville, Tennessee 37203
?
mi
from
Nashville, TN
Click here to add this to my saved trials
333 Cedar St
New Haven, Connecticut 06504
(203) 432-4771
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
738 Library Road
Rochester, New York 14642
?
mi
from
Rochester, NY
Click here to add this to my saved trials